Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor with potent antitumor activity. It primarily inhibits VEGFR1-3 (IC50s = 22, 4, and 5.2 nM, respectively), as well as other receptor tyrosine kinases including FGFR1-4, PDGFRα/β (IC50s = 46 and 51 nM), KIT (IC50 = 100 nM), and RET. It suppresses angiogenesis and tumor proliferation by blocking these signaling pathways. In preclinical models, lenvatinib significantly reduces tumor growth and induces tumor regression. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.